ENDRA Life Sciences Q2 2026 Earnings Report

ENDRA Life Sciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.84
• Beat/Miss: N/A
• One Year Ago EPS: N/A

ENDRA Life Sciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.10 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

ENDRA Life Sciences Announcement Details

• Quarter: Q2 2026
• Date: 8/13/2026
• Time: Before Market Opens
• Conference Call Date: Friday, August 14, 2026
• Conference Call Time: 4:00PM ET

ENDRA Life Sciences (NASDAQ:NDRA), Inc. (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems. Using patented algorithms and specialized hardware, the system captures thermoacoustic signals generated when tissue is exposed to low-power microwave pulses. These signals enable clinicians to visualize temperature distributions during procedures such as radiofrequency ablation, microwave ablation and high-intensity focused ultrasound. The company collaborates with hospitals, academic research centers and medical device partners to conduct preclinical and clinical studies that validate the performance and utility of TAEUS technology.

The company holds a growing portfolio of issued and pending patents across the United States, Europe and Asia, and it is advancing toward broader regulatory clearances and international market entry. ENDRA’s leadership team is led by President and Chief Executive Officer David Kaiss, who brings two decades of experience in medical device development, regulatory affairs and commercialization. Under his direction, the company has expanded its R&D capabilities, strengthened manufacturing partnerships and established key distribution channels to support future product launches.